How JACARDI can support the implementation of the EU Safe Hearts Plan

Benedetta Armocida, coordinator of JACARDI, presented the Joint Action’s role in shaping screening and early detection approaches under the Safe Hearts Plan, during a dedicated webinar organized by the European Commission.

On 15 January 2026, the European Commission hosted the first stakeholder webinar dedicated to the Safe Hearts Plan, the EU’s first-ever cardiovascular health plan, adopted on 16 December 2025. The online event brought together nearly 500 stakeholders from across Europe and provided a key platform to exchange views on how to support the implementation of the Plan and its flagship initiatives [1].

The webinar [2] marked an important milestone in the roll-out of the Safe Hearts Plan, which aims to tackle cardiovascular diseases (CVDs), the leading cause of mortality in the European Union, through coordinated action on prevention, early detection and screening, and treatment, care and rehabilitation, while addressing cross-cutting challenges such as data and digitalisation, research and innovation, and health inequalities.

Opening the meeting, Commissioner for Health and Animal Welfare, Olivér Várhelyi, underlined the urgency of action and the importance of collaboration with stakeholders to turn the Plan into concrete results.

“Cardiovascular diseases remain Europe’s number one killer, placing a growing burden on our health systems, societies and economies. With the Safe Hearts Plan, we now have a strong policy tool at EU level, but its success will depend on close cooperation with Member States and stakeholders to make it a reality,” said Commissioner Várhelyi.

Supporting early detection and screening

During the webinar, the coordinators of key Joint Actions, JACARDI and JA PreventNCD, presented how their work contributes to the implementation of the Safe Hearts Plan. Dr Benedetta Armocida, coordinator of JACARDI, highlighted the Joint Action’s strong alignment with Pillar 2 of the Plan: early detection and screening, including the flagship initiative on an EU Protocol on Health Checks for CVDs.

JACARDI brings together 21 countries and 81 partners, working to translate EU priorities into concrete, country-level implementation. In particular, Work Package 8 on screening high-risk populations, led by Hanna Tolonen and Luigi Palmieri, is developing common protocols and tools to support Member States in the design, organisation and sustainability of effective screening programmes.

“We are testing and implementing practical solutions that can support the Safe Hearts Plan on the ground. Our pilot projects on early detection and screening aim to generate evidence and tools that help Member States reach high-risk populations, while embedding equity and sustainability across all activities. The aim is to provide further evidence and the result of our pilots to support the implementation of the European plan,” said Dr Armocida.

In practice, JACARDI is implementing 19 pilot projects focused on screening for CVDs and diabetes across different European countries, assessing the feasibility of diverse screening approaches. The Joint Action has also developed an online risk assessment tool and decision guide, supporting professionals in selecting appropriate risk prediction methods.

Addressing inequalities is a core priority for JACARDI, fully aligned with the Safe Hearts Plan. Across its 143 pilot projects, the Joint Action promotes equity and diversity, targeting both the general population and high-risk groups, with a focus on integrated care pathways, self-management and social participation.

The webinar also showcased the strong alignment between the Safe Hearts Plan and other EU initiatives. Knut Jønsrud, project manager of JA PreventNCD, emphasised the importance of addressing key risk factors and reducing social inequalities through a life-course approach.

“Several flagship initiatives of the Safe Hearts Plan, such as modernising tobacco control legislation and strengthening health literacy, are closely aligned with our work. A people-centred, equity-focused approach and cross-sectoral collaboration are essential to achieving lasting impact,” said Jønsrud.

A coordinated EU response

Antonio Parenti, director for Public Health, Cancer and Human Security in the Directorate General for Human and Food Security of the European Commission (DG SANTE), stressed the scale of the challenge posed by CVDs and the need for decisive, coordinated action at EU level.

“CVDs cost the EU more than €280 billion every year. Without strong and coordinated action, this burden will continue to grow, affecting future generations, health systems and economic resilience. The Safe Hearts Plan is our collective response to this challenge,” Parenti stated.

He highlighted the Plan’s three pillars and its ten flagship initiatives, designed to improve population health, foster innovation and support sustainable healthcare systems. Prevention remains a cornerstone of the Plan, as nearly 80% of CVDs can be prevented through lifestyle changes, alongside strengthened, patient-centred and multidisciplinary care [3].

Next steps

The European Commission will now collect and analyse the feedback and ideas shared by stakeholders during the webinar. A second stakeholder webinar is planned for the second half of 2026, ensuring continued dialogue as the Safe Hearts Plan moves into its implementation phase.

For JACARDI, the webinar confirmed the relevance of Joint Actions as key instruments to support EU health policies and demonstrated how collaborative, evidence-based approaches can help reduce the burden of CVDs across Europe.

[1] About the Safe Hearts Plan flagship initiatives

Adopted in December 2025, the EU Safe Hearts Plan is underpinned by ten flagship initiatives designed to deliver clear EU added value across prevention, care and innovation, while supporting Member States in addressing cardiovascular diseases in a coordinated and sustainable way:d

• A lifelong, personalised and digitally enabled prevention programme – ‘EU cares for your heart’
• Empowering consumers through information on food processing in the EU
• Modernising tobacco control legislation
• The Commission will examine which appropriate tools, including possible financial actions, could be deployed to support/fund public health actions in the field of primary prevention and stimulate food reformulation and healthier consumer choices
• Proposal for a Council recommendation on vaccination against respiratory infections as a preventive measure for cardiovascular diseases
• EU protocol on health checks for cardiovascular diseases
• Proposal for a Council recommendation on personalised treatment and monitoring of cardiovascular diseases
• Incubator for innovation and integration of AI and digital technologies in cardiovascular healthcare
• EU cardiovascular health inequalities dashboard
• Cardiovascular Disease Research and Innovation Roadmap

[2] Stakeholder Webinar the Safe Hearts Plan – Meeting documents
[3] Questions and answers on the EU Safe Hearts Plan

New online risk test by the Finnish Diabetes Association garners over 120,000 users in just one month

A groundbreaking new digital health initiative in Finland is empowering individuals to assess their risk of developing some of the country’s most common chronic illnesses, all from the comfort of their homes. This tool has been developed as part of a pilot program within JACARDI’s Work Package on screening by the Finnish Institute for Health and Welfare (THL) and the Finnish Diabetes Association.

The new online risk test has already garnered over 120,000 users in just one month, signaling a widespread public interest. In fact, drawing from extensive population-level health data, the tool estimates a person’s likelihood of developing: type 2 diabetes, cardiovascular diseases, and memory disorders (such as dementia). The risk for type 2 diabetes and heart disease is projected over 10 years, while memory disorders are evaluated over a 20-year timeline.

The test was developed by a team of experts, including Prof. Jaana Lindström, Research Manager at THL and Sari Koski, Director of Diabetes Courses and Knowledge Production at the Finnish Diabetes Association, under JACARDI’s Work Package on Screening, led by Hanna Tolonen from THL. It does not function as a diagnostic tool, yet it offers a general risk assessment based on an individual’s lifestyle and health background, providing valuable insights even before symptoms emerge. It is especially helpful for individuals who may not yet have access to clinical testing or regular medical evaluations.

The test is available online and can be completed in minutes, anonymously and free of charge. It is designed for adults of all ages and is especially relevant for those who are unaware of their risk factors. It can be used independently at home.

Each user receives a personalized summary of their risk, along with science-backed lifestyle suggestions. These include advice in areas, such as diet and nutrition, physical activity, sleep and recovery, and stress management.

By taking the test, individuals are encouraged to make small but impactful changes to their daily habits, changes that could significantly reduce their chances of developing chronic illnesses in the future.

Since its launch in late May 2025, the test has exceeded expectations; the section related to memory disorders has seen particularly high engagement.

This level of adoption underscores a growing interest among the Finnish population in self-directed health promotion and self-care. The success of the initiative also reflects how digital tools can complement traditional healthcare services by raising awareness, prompting early action, and reducing long-term healthcare costs.

Health authorities are enthusiastic about the test’s potential. Prof. Jaana Lindström, from THL, emphasized its preventive power, stating that recognizing risk is key to taking action in time.

Sari Koski, representing the Finnish Diabetes Association, highlighted the importance of modest lifestyle adjustments by saying that even small changes can lead to significant health benefits over time.

This perspective is supported by stark national statistics. Every year in Finland:

• Approximately 23,000 people are diagnosed with type 2 diabetes
• Around 22,000 with coronary artery disease
• About 23,000 begin experiencing memory-related disorders

These figures underline the urgent need for tools that enhance citizens’ awareness of chronic disease risk factors and promote early detection and lifestyle interventions.

For this reason, the launch of this new test quickly gained widespread attention, as the campaign was covered extensively by both major national and local media outlets across Finland. Leading publications highlighted the test’s potential to empower individuals to take control of their health. Regional news platforms played a key role in disseminating the information, ensuring that citizens across the country, from urban centers to rural municipalities, were informed about the tool.

The risk test serves not only as a personal wellness tool but also as a potential model for broader public health efforts. This strategy is not only beneficial for the individual but also contributes to the sustainability of the healthcare system.

Moreover, initiatives like this one are economically sensible: they help curb the rising costs of treating chronic conditions and allow more people to stay healthier and more productive for longer.

Finland’s new online risk test represents a timely and impactful tool for public health promotion. While not a replacement for medical diagnosis, it opens the door to greater personal responsibility and awareness. By bridging digital innovation with health promotion, it empowers citizens to act before illness strikes, and that might just be the key to a healthier future for all.

“There is a positive story to be told here” — what we learned at the DigiCare4You Workshop

In line with HaDEA’s commitment to foster synergies and share knowledge across EU health initiatives, JACARDI actively engages with a wide portfolio of projects – from Joint Actions and EU4Health grants to Horizon-funded interventions. JACARDI team members recently attended the DigiCare4You Capacity Building and Recommendations Development Workshop with International Stakeholders, held in Lisbon during the annual ICIC conference.

The event underscored how ongoing stakeholder engagement is vital to disseminate results, explore upscaling opportunities, develop evidence-based national policies and lay the groundwork for future cross-country collaborations. We invite readers to learn more about this ambitious intervention – running in parallel to our own pilot implementations – which is already demonstrating early results, implementation insights, and an inspiring commitment to meaningful change in health self-management.

A people-centric, digital health solution for preventing and managing diabetes and hypertension

The Horizon2020-funded DigiCare4You project offers a new model for the early prevention and management of type 2 diabetes (T2D) and hypertension (HTN) by engaging schools, communities, and healthcare systems in an intersectoral approach. At its core, the project empowers families and connects health and education sectors, equipping individuals with digital tools to better manage their health.Building on the evidence-based Feel4Diabetes study, DigiCare4You is being implemented in two high-income (Greece, Spain) and two middle-income countries (Albania, Bulgaria), targeting over 10,000 families across socio-economic groups.

Screen, support, empower – the DigiCare4You approach

DigiCare4You applies a two-step screening model leveraging existing child growth monitoring activities in schools and health centers through which parents and caregivers are approached to complete the FINDRISC questionnaire as the first screening step. Adults identified as at risk are then referred for a second screening, which includes anthropometric and clinical assessments to detect conditions such as prediabetes, type 2 diabetes, or hypertension.

Those confirmed at risk are subsequently invited to join the DigiCare4You two-year, mHealth-supported intervention programme, focused on lifestyle change, self-management, and family support. A multilingual mobile app offers access to health data, tracking tools, and educational resources and even recipies. Importantly, the intervention supports healthier behaviors in both adults and children through school and community-based activities.

DigiCare4You combines digital innovation, equity-driven outreach, and participatory research, while integrating into existing systems and investing in health professional training – ensuring sustainable, real-world impact.

Early results revealed: first findings inspire confidence

The Capacity Building and Recommendations Development (CBRD) Workshop gathered international experts at the midpoint of project implementation to review progress and shape the upcoming Roadmap for Scale-Up.Prof. Brian Oldenburg elevated the spirit of the event stating that: “Early findings are promising enough to say that there is a positive story to be told here.” Indeed, early results are compelling:

• Fewer adults with intermediate hyperglycaemia progressed to T2D; many returned to normal glucose levels.
• Participants with T2D improved their HbA1c.
• Adults with obesity experienced weight loss, BMI reduction, and lower cholesterol—without increased medication reliance.

From research to real-world impact

The workshop emphasized the transition from effectiveness to implementation research – examining how interventions work in real-life conditions. Dr Rajesh Vedanthan facilitated a compelling discussion in which implementers candidly shared successes and challenges.

Key takeaways from country implementers:

• Strong consensus: “Yes, we would start and do it again.”
• Motivation stems from seeing behavior change within families—especially when children and caregivers reinforce each other’s progress.
• Burnout among healthcare staff is a concern—but aligning DigiCare4You with existing systems proved an effective strategy.
• Local ownership and trust, especially through primary care systems and schools, were pivotal.
• Participants emphasized the importance of engaging families holistically, with one Bulgarian team member noting how “changing the behavior at home” can be one of the most lasting outcomes.

Additionally, one noted barrier to engagement was previous unsuccessful attempts at weight control, highlighting the need for tailored motivational support.

Cost-effectiveness, scalability, and the road ahead

Preliminary analyses suggest strong cost-effectiveness, especially when targeting adults with intermediate hyperglycaemia in MICs. A Scalability Decision Support Tool was developed to assess implementation readiness across five domains: NCD care context, digital literacy, support systems, screening capacity, and digital integration. These insights inform the forthcoming Roadmap for Scale-Up.

JACARDI Relevance

The presence of experts involved in both JACARDI and DigiCare4You highlights the existence of a vibrant, cross-country network of professionals dedicated to cardiovascular and diabetes care. The workshop featured members of the JACARDI Stakeholder Advisory Board, including a policy advisor from the European Diabetes Federation, epidemiologist and researcher from EUPHA, healthcare professionals involved in the pilot implementation in Portugal, representatives from the industry developing digital tools, and communication experts. Together, these individuals demonstrate the strength of this interconnected community.

Such events provide valuable opportunities to learn, grow and exchange knowledge, and have the potential to shape and enhance the quality of ongoing interventions. Given the different timelines of these projects, the initial findings of the DigiCare4You project can provide valuable insights for the JACARDI teams, given that the implementation of the pilots has only just begun.

Looking ahead

In its final year, DigiCare4You will focus on completing the intervention, finalizing cost-effectiveness studies, and refining its scalability tools. A second CBRD workshop will present final results and a full Roadmap for Scale-Up, providing a concrete guide for policy and replication.

As the burden of type 2 diabetes (T2D) in Europe is expected to reach 72 million people by 2050, DigiCare4You is emerging as a promising prevention model. “We design a programme, and when we start to implement it, we are confronted with the reality on the ground. Reality is revealed, and we act according to people’s needs,” said Prof. Yannis Manios, Project Coordinator. Meeting people where they are – with empathy, innovation and commitment – may be the most powerful intervention of all.

Discover more about the DigiCare4You project here.

JACARDI’s voices on the scientific stage across Europe

The first half of 2025 has been a busy and productive time for JACARDI, with consortium members sharing key findings and pilot implementation highlights at leading scientific conferences across Europe. These contributions, spanning health literacy, integrated care, biomarker-based screening, and health economics, demonstrate the depth and scope of the work underway across multiple work packages.

Spotlight on ICIC25 – Lisbon, Portugal | May 14–16, 2025

JACARDI had a strong presence at the 25th International Conference on Integrated Care (ICIC25) with three distinct contributions representing different work packages:

Irati Erreguerena (Work Package 6 – Health literacy) delivered an oral presentation on a co-designed health literacy program for adolescents in the Basque Country, Spain. Her talk highlighted how WHO’s Health Literacy Development Model, and the Ophelia (Optimising Health Literacy and Access) co-design methodology were applied to empower younger populations with knowledge and tools for chronic disease prevention.

Yhasmine Hamu (Work Package 9 – Integrated care pathways) presented on the implementation of a value-based integrated care model, sharing strategies to address care fragmentation and improve outcomes for people with chronic conditions.

Gergely Varga (Representing both Work Package 9 – Integrated care pathways and Work Package 5 – Methodological framework) contributed a poster that outlined a situational analysis methodology designed to support integrated care.

Faculty of Public Health Summer Scientific Meeting – Dublin, Ireland | May 20–21, 2025

Sonja Moore (Work Package 8 – Screening) presented findings from a scoping literature review on the use of natriuretic peptides in cardiovascular risk stratification and management. Her poster focused on current strategies and approaches for using these biomarkers in patient populations without diagnosed heart failure, a topic gaining traction in preventive cardiology. The review aimed to inform more targeted screening protocols and identify gaps in clinical practice across Europe.

COMET Conference – Poznań, Poland | June 25–27, 2025

Richard Osborne (Work Package 6 – Health Literacy) represented JACARDI at the 23rd International and Interdisciplinary Conference on Communication, Medicine, and Ethics (COMET). His oral presentation focused on scaling up health literacy development as a strategy to prevent and manage non-communicable diseases. The talk stressed the need for strategic investment in communication and co-design at the system level.

1st European Public Health Economics Conference
– Palermo, Italy | June 26–27, 2025

Katie Ellwood (Work Package 8 – Screening) presented a pilot study from JACARDI aiming to establish the most cost-effective threshold for using NT-proBNP blood marker in cardiovascular disease (CVD) risk stratification. The analysis models the impact of different thresholds over a 30-year horizon in a large population cohort. This pioneering work within JACARDI bridges clinical practice with health economics, helping to inform sustainable, evidence-based screening strategies.

These scientific initiatives reflect JACARDI’s commitment to knowledge-sharing, collaboration, and measurable impact. Consortium members not only showcased research but also engaged with policymakers, practitioners, and academics, advancing the mission to improve cardiovascular and diabetes outcomes across Europe. The autumn season offers a variety of relevant conferences, kicking off right at the end of summer with the Congress of the European Society of Cardiology, taking place from 29 August to 1 September.

From evidence to impact: a united call for equity-driven and sustainable action on NCDs

• JACARDI, JA PreventNCD, WHO Europe, OECD and the European Commission’s DG SANTE have published a joint Comment in The Lancet Regional Health, based on the findings of the newly published report ‘Avoidable mortality, risk factors and policies for tackling NCDs: leveraging data for impact’, by WHO Europe.
• The Comment underscores the critical role of cross-national collaboration in translating WHO findings into actionable policies, with a focus on equity, data-driven solutions, and integrated care pathways.
• These organizations call for an accelerated, harmonised and equity-driven European agenda on non-communicable diseases.

Non-communicable diseases (NCDs) remain the leading cause of death and disability in Europe, and recent trends reveal both progress and setbacks. While tobacco use, hypertension prevalence, and alcohol consumption have declined since 2010, obesity and diabetes rates continue to rise alarmingly, and physical inactivity shows no signs of improvement. This mixed picture is compounded by a slowdown in the implementation of vital public health policies since the COVID-19 pandemic.

These findings are discussed in a Comment published in The Lancet Regional Health and developed through a collaborative effort bringing together JACARDI, JA PreventNCD, WHO Europe, OECD (Organisation for Economic Co-operation and Development), and the European Commission’s DG SANTE. The publication summarises the findings of the report Avoidable mortality, risk factors and policies for tackling noncommunicable diseases – leveraging data for impact: monitoring commitments in the WHO European Region ahead of the Fourth United Nations High-Level Meeting, by WHO Europe, reinforcing the urgency of renewed action. It emphasises the need for comprehensive solutions that prioritise strengthening health systems, accelerating the implementation of proven interventions, effective policies, and integrating equity-driven approaches.

The Comment presents key insights taken from the WHO Europe Report on the current state of NCD prevention and management in Europe. It highlights key challenges, such as the decline in the number of countries that have fully implemented NCD surveys, which fell from 28% in 2021 to 19% in 2023, and the reduction in the number of countries with operational multisectoral NCD strategies, which decreased from 60% to 55% during this period.

Despite these challenges, the authors note that 85% of European countries have adopted management guidelines for the four major NCDs: cardiovascular diseases, cancer, diabetes, and chronic respiratory diseases; demonstrating significant foundational progress.

“These figures paint a complex picture. Despite decades of progress in reducing premature mortality from the four major NCDs prioritised by global agenda, currently the region is off track to meet its 2025 targets. Moreover, the rise in obesity and diabetes and the slowdown in policy implementation highlight the urgent need to reinvigorate our efforts”, comments first author Dr Benedetta Armocida, from the Department of Cardiovascular, Endocrine-metabolic Diseases and Aging at Istituto Superiore di Sanità-ISS, Rome (Italy) and Coordinator of JACARDI.

The Scientific Coordinator of JA PreventNCD, Prof Knut-Inge Klepp, concurs and is particularly concerned regarding the slowdown in the implementation of population level policy interventions:

“We know how critical such policies are if we are to succeed in having a significant and lasting impact across population groups in Europe. Inequalities in NCD-related health remain a key challenge across and within European countries”.

Driving change

The European Union’s flagship initiatives under the EU4Health Programme are pivotal in addressing these challenges. JACARDI and JA PreventNCD are at the forefront of strengthening cross-national collaboration and implementing integrated strategies for NCD prevention and management.

JA PreventNCD targets primary prevention by tackling root causes such as unhealthy diets, tobacco and alcohol use, and lack of physical activity. JACARDI, meanwhile, focuses on secondary and tertiary prevention, aiming to enhance outcomes for cardiovascular diseases and diabetes through evidence-based interventions and integrated care pathways. Together, these initiatives exemplify the EU’s commitment to tackling NCDs across the care continuum, supported by a combined budget of €160 million and participation from 27 European countries.

The WHO NCD Global Monitoring Framework, which includes nine global voluntary targets, notably the headline goal of a 25% reduction in premature mortality from NCDs by 2025, is about to expire. That is why the authors provide a clear roadmap for advancing the fight against NCDs, ensuring systematic policy implementation and strengthening data infrastructures to translate commitments into measurable health outcomes.

“There are no more excuses. We have the knowledge and the tools. What remains is the will to implement them swiftly and hold ourselves accountable for delivering real results. This is not just a matter of public health; this is a matter of justice, security, and competitiveness, and a shared future”, says Dr Hans Henri P. Kluge, World Health Organization Regional Director for Europe.

Armocida and Klepp underscore the power of collaboration in achieving meaningful change: “We truly believe this joint effort reflects the strength and unity across Europe, bringing together a diverse group of organisations, initiatives, and stakeholders committed to reducing the burden of NCDs. The collaborative authorship of this Comment itself serves as an example of the collective commitment and shared vision needed to address one of the region’s most pressing public health challenges.”

The Comment calls for an accelerated, harmonised, and equity-driven European agenda on NCDs, particularly in the lead-up to the 2025 UN High-Level Meeting on NCDs.

The JA PreventNCD and JACARDI Joint Actions encourage policymakers, researchers, and public health advocates to explore this vital publication and join in building a healthier, more equitable future for Europe.

JACARDI (Grant Agreement 101126953) and JA PreventNCD (Grant Agreement 101128023) projects have received funding from the EU4Health Programme 2021-2027.

Milka Sokolović: JACARDI is a beacon of proactive change in Europe’s healthcare landscape

Promoting healthy eating habits and regular physical activity can greatly reduce the risk of non-communicable diseases, but the responsibility cannot fall solely on individuals. This is the approach championed by Milka Sokolović, Director General of EPHA, the European Public Health Alliance, and a member of JACARDI’s Stakeholder Advisory Board. Strong public health policies are crucial in ensuring access to healthy food options and encouraging physical activity. JACARDI plays a key role in driving these efforts, fostering cross-sector collaboration and advocating for policies that empower individuals to make healthier choices. At the same time, we must harness the power of civil society and advocate for stricter regulations on industries that harm health, including the tobacco, alcohol, and ultra-processed food sectors.

What does JACARDI mean to you and your organization in terms of its mission and values?

For EPHA and myself, JACARDI is a crucial initiative in combating cardiovascular diseases, diabetes, and other non-communicable diseases in Europe. Its focus on prevention, disease management, and cross-sectoral collaboration aligns with EPHA’s values of health equity and evidence-based policy. JACARDI’s comprehensive approach addresses these conditions and considers the broader social and commercial determinants of health, enhancing our joint advocacy for sustainable public health policies in the EU.

Based on your experience in public health, what do you consider the main barriers to reducing the prevalence of cardiovascular disease (CVD) and diabetes in the EU, and how can these challenges be addressed?

Public health, particularly regarding non-communicable diseases like CVDs and diabetes, faces many challenges, including the influence of health-harming industries and varying public health policies across member states. To effectively counter these diseases we advocate for more stringent regulations on industries that negatively impact health, such as the tobacco, alcohol and ultra-processed food sectors. It is also vital to improve the coordination and integration of health policies across the EU for greater efficiency and uniformity.

Bridging the gap between political action and healthcare practice requires early stakeholder input in policy making. Leveraging the collective strength of civil society to advocate for these changes and prioritising public health in the political agenda is essential. JACARDI’s work addresses many of these critical areas.

In your experience, what are the most critical economic and political factors to consider when implementing health initiatives across different global settings?

Effectively addressing cardiovascular disease and diabetes requires understanding both economic and political contexts. Economically, resource availability and stable health financing are crucial for sustaining initiatives. Politically, long-term commitment from governments and stakeholders is necessary to implement robust health policies. Early engagement with policymakers ensures health initiatives align with regional and national priorities, improving their effectiveness.

The JACARDI model, emphasising cross-country and sector cooperation, including other joint actions like the JA PreventNCD, offers a blueprint for addressing these challenges. Through collaboration, JACARDI enhances the implementation of adaptable and resilient health strategies, serving as a framework for other global health initiatives.

What role do lifestyle changes, such as diet and physical activity, play in the prevention and management of CVD and diabetes, and how can public health policies better support these changes?

Lifestyle changes are fundamental in the prevention and management of cardiovascular diseases (CVD) and diabetes. Encouraging healthy eating habits and regular physical activity can significantly reduce the incidence of these conditions, but it cannot rely solely on the individual. Public health policies play a key role by facilitating access to healthy food options and promoting physical activity through the creation of safe and accessible public spaces.

Integrating lifestyle interventions into national health policies can have a positive impact on public health. From JACARDI’s perspective, this is being addressed through initiatives that improve health literacy and encourage active participation from diverse populations. Furthermore, educational campaigns and programmes in schools and workplaces can motivate behavioural changes.

Finally, comprehensive policy approaches are crucial and it is essential that public policies tackle health misinformation and provide citizens with the necessary tools to assess the information that they are exposed to.

How do you see JACARDI’s role in addressing the growing prevalence of cardiovascular disease and diabetes in Europe?

JACARDI is a beacon of proactive change in Europe’s healthcare landscape. Its comprehensive approach to disease management and prevention addresses the rising prevalence of CVD and diabetes, focusing on prevention, early diagnosis, and effective management.

Beyond immediate health interventions, JACARDI integrates diverse healthcare approaches, ensuring inclusivity and adaptability for both urban and underserved populations. This ensures no one is left behind. Through these efforts, JACARDI strengthens European health systems’ ability to manage and prevent these diseases, promoting a healthier and more equitable future for all European citizens.

In a career that spans a quarter of a century and three countries, it was her unceasing quest for more impact and purpose in her work that brought Milka Sokolović to EPHA. As Director General, she instigates alliances and forges partnerships, while advocating for equitable solutions to European public health challenges, insisting on the vital role of civil society in reaching those solutions.

Milka Sokolović holds a degree in Biology from the University of Belgrade, and a PhD in Medicine from the University of Amsterdam. Through her research and academic roles at the Universities of Belgrade and Amsterdam, and her leadership roles at the European Food Information Council (EUFIC) and the European Nutrition Leadership Platform (ENLP), she has developed a remarkable expertise in scientific research, communication, and strategic partnerships.

Milka is skilled at developing and implementing organisational strategies, equipped with robust leadership competencies, and armed with ample enthusiasm, driven by Goethe’s “Knowing is not enough, we must apply. Willing is not enough, we must do.”

Learn more about EPHA here and connect with Milka Sokolović here.

Francesco Cosentino: Policy change can only happen when it is driven both at EU and national level

As the European Commission prepares to launch the European Cardiovascular Health Plan, recognizing the strong link between cardiovascular disease and diabetes is more important than ever. However, for real impact, the plan must provide funding that reflects the scale of the CVD burden, says Francesco Cosentino, Vice-President of the European Society of Cardiology (ESC) from 2020 to 2022, and a member of JACARDI’s Stakeholder Advisory Board. JACARDI’s work in optimizing the availability of health data can play a vital role in shaping future policies and ensuring data availability will also be key to improving adherence to guidelines.

What significance does JACARDI hold for you and your organization in terms of its mission and values?

The mission of the European Society of Cardiology (ESC) is to reduce the burden of cardiovascular disease (CVD). Our society is very supportive of the great work being undertaken through JACARDI, which aims to support European countries in reducing the burden of CVD and diabetes and improve quality of care for the individuals affected.

How do you see JACARDI’s role in tackling the increasing prevalence of cardiovascular disease and diabetes in Europe?

I believe that JACARDI, through its numerous science-based pilot projects in 18 EU countries and with its network of 76 partners, has great potential to foster community spirit, knowledge sharing and to create value for tackling the increasing prevalence of CVD and diabetes across Europe. I think that JACARDI’s main strength is the integrated approach addressing both diseases simultaneously with a focus on the entire patient journey.

How do you think JACARDI will influence future collaboration on cardiovascular disease and diabetes prevention in Europe?

JACARDI specifically reflects the realities of patients who live with two comorbidities. We know CVD remains the predominant cause of death and disability in Europe. In the European Union, 62 million people live with CVD and 5 million new cases are diagnosed every year. In addition, 1 in 10 adults live with diabetes. What we also know is that people with diabetes have a two to three times higher cardiovascular risk than people without diabetes. They also see their life expectancy reduced by 10-14 years.

It is important to diagnose CVD and diabetes as early as possible to prevent complications and reduce healthcare costs. Recognizing these interlinkages between these two comorbidities is also crucial in the context of the incoming European Cardiovascular Health Plan from the European Commission. I believe that diabetes will be included within this plan.

So, joint health checks based on common risk factors for both diseases, such as high body mass index (BMI), high blood pressure, tobacco and alcohol consumption, high blood glucose and high LDL cholesterol are sensible and cost-effective options for the identification of high cardiovascular risk in individuals.

Based on your experience chairing the ESC Guidelines on Diabetes and Cardiovascular Disease, how can JACARDI’s research contribute to shaping future clinical guidelines in Europe?

Our ESC Guidelines on Diabetes and Cardiovascular Disease are an excellent tool to implement evidence-based, person-centered treatment strategies. This is what we call personalized medicine, which we know is effective in reducing cardiovascular risk in patients with diabetes. I believe that findings from JACARDI may potentially help the implementation of our guidelines in the daily clinical practice.

A critical step is ensuring that the clear target outlined in the ESC guidelines, to achieve better outcomes for people living with diabetes and CVD, is met for all patients. However, we are not there yet.

In this regard, data availability, data sharing and utilization are really crucial to improve patients’ and healthcare professionals’ adherence to the guidelines. One of the Work Packages of JACARDI aims to optimize the way individuals, communities, and organizations access, understand and use health information. These can be very helpful in shaping future guidelines.

With your background in cardiovascular pharmacology, what role do you think pharmacological innovations will play in complementing JACARDI’s efforts to reduce the burden of cardiovascular disease and diabetes?

I believe that a wide range of stakeholders have an important part to play in improving cardiovascular health in our population. This also includes the innovations coming from pharma and device companies. We hope that the innovation pipeline will continue to improve in the coming years as many clinical needs remain unmet.

Collaboration is definitely key and this is why the ESC is also a proud partner of the European Alliance for Cardiovascular Health (EACH), which comprises 21 leading organizations, including medical societies, industries and patients organizations.

Given your leadership experience in the European Society of Cardiology, how can JACARDI help drive policy changes at the European level to improve cardiovascular and diabetes care across diverse healthcare systems?

The ESC together with the European Alliance for Cardiovascular Health, has been advocating for a European Cardiovascular Health Plan for many years. Now finally, the policy context is extremely positive. The President of the EU Commission put CVD on the agenda and the Commissioner for Health has committed to developing a European Cardiovascular Health Plan, similar in ambition to Europe’s Beating Cancer Plan.

This was announced on the 3rd of December 2024, on the same day the Ministers of Health from the 27 Member States of the European Union approved the Council Conclusions on the Improvement of Cardiovascular Health in the EU.

It is clear that the plan is coming. What we need to ensure is that there is significant funding attached to the plan, proportionate to the burden of CVD. I believe the magnitude of work and effort from JACARDI also shows the interest at Member State level of this being a priority topic.

Policy change can only happen when it is driven at both the EU and national levels. And JACARDI showcases this important complementary nature with 80% of the close to €60 million in funding coming from the EU and the remaining 20% from the 21 participating European countries. I think collaboration is key and the driving force behind making real progress.

Prof. Francesco Cosentino is a Professor of Cardiology at the Karolinska Institute and University Hospital in Stockholm, Vice-President of the European Society of Cardiology (ESC) from 2020 to 2022 and co-Chair of the ESC Advocacy Committee from 2022 to 2024. He chaired the 2019 ESC Guidelines on Diabetes and Cardiovascular Disease and serves as Deputy Editor of the European Heart Journal and Consulting Editor of Cardiovascular Research Journal.

As a leading researcher, he has received grants and awards from national and international research councils and private foundations and has authored over 200 original articles in top-ranking, peer-reviewed journals. As a member of JACARDI’s Stakeholder Advisory Board, he contributes to work packages focused on data insights (WP7), screening (WP8), patient pathways (WP9), and patient self-management (WP10).

Learn more about Francesco Cosentino and his work here, and about ESC here.

Bart Torbeyns: JACARDI’s unified strategy makes perfect sense

Meet Bart Torbeyns, the Executive Director of the European Diabetes Forum (EUDF) and a pivotal voice in the fight against diabetes and cardiovascular disease. As a member of JACARDI’s Stakeholder Advisory Board, Bart commends JACARDI’s integrated approach to addressing both diseases simultaneously. “For primary care physicians and patients managing multiple chronic conditions, JACARDI’s unified strategy makes perfect sense,” he observes. Bart passionately advocates for the elimination of discrimination against individuals living with diabetes and establishes that the critical step for lowering its burden is establishing clear targets through better data.

What significance does JACARDI hold for you and your organization in terms of its mission and values?

At its core, JACARDI is about improving outcomes for people living with diabetes and cardiovascular disease. While I work for the united diabetes community, we’re acutely aware that many of the people living with diabetes also face cardiovascular risks and, in some cases, complications. What makes JACARDI so valuable is its focus on the entire patient journey, starting with health literacy, labor participation, patient pathways, screening, and better management. These areas are still critically needed across many European countries.

For example, in the area of screening, we know that up to one in three people with diabetes are unaware they have the disease, reaching one in two in certain countries. These individuals, by definition, are not receiving education or proper treatment, leading to severe complications. Addressing these gaps is fundamental to the work we do.

How do you think JACARDI’s work aligns with promoting the overall well-being of patients?

The well-being of people with diabetes is crucial, and JACARDI’s work aligns perfectly with this focus. Health literacy and labor participation are especially vital in this context. Self-management is another key element. When people are well-treated, well-managed, and educated about their condition, they gain confidence in how to handle it, which provides peace of mind.

This is particularly important for families, parents, and teachers who support younger individuals with type 1 or type 2 diabetes. The better they understand the disease, the better the overall well-being of those involved.

Labor participation is another critical area. Unfortunately, discrimination against people with NCDs, including diabetes, still exists. Many individuals hesitate to reveal their condition, for instance, I know people who would never inject insulin publicly and instead hide to do it. It’s crucial to combat this stigma. People with diabetes can make valuable contributions to the economy and society. I’ve encountered many brilliant individuals with diabetes, and ensuring they have opportunities to participate fully is essential for their well-being but also for our economy and society. The work JACARDI is doing on labor participation is a prime example of addressing these challenges.

What are the most critical next steps for Europe in addressing the dual burden of cardiovascular disease and diabetes?

A critical step is establishing clear targets to achieve better outcomes for people living with diabetes and cardiovascular disease. This process begins with better data, improving its availability, sharing, and utilization. For instance, many European countries don’t even know how many people in their population have diabetes. Without this basic information, it’s difficult to make progress.

Once we have reliable data, the next step is setting targets to improve results and prevent complications. What I particularly appreciate about JACARDI is its collaborative approach, bringing together the cardiovascular and diabetes communities. There’s so much we can learn and share from each other.

By adopting a patient-centric perspective, it’s clear that many people with diabetes are at high risk of developing cardiovascular disease, and the reverse is also true. Often, we think in silos, creating separate plans for diabetes, obesity, or cardiovascular disease, but for primary care physicians and patients managing multiple chronic conditions, JACARDI’s unified strategy makes perfect sense, and that’s an approach I fully support.

Recently the new Commissioner for Health and Animal Welfare, Mr. Várhelyi, announced he will propose a comprehensive cardiovascular health plan that will also address diabetes and obesity. We very much welcome such a comprehensive approach and we are confident that JACARDI’s deliverables will be consolidated in this new plan.

Bart Torbeyns is a dedicated leader in public health policy and advocacy, with a focus on improving healthcare systems and addressing chronic diseases. With master’s degrees in Pharmacy and Business Economics from the University of Louvain, he has contributed to initiatives like the SUGAR and the DYSIS studies, generating vital local data for diabetes and atherosclerosis care in Belgium. He has worked as Head of Public Affairs in Belgium and Europe at MSD and Sanofi, and analyzed healthcare systems and developed strategies to promote equitable access to care. Now serving since 2020 as the Executive Director of the European Diabetes Forum (EUDF), he works to advance collaborative, patient-centered policies addressing diabetes and cardiovascular health across Europe.

Learn more about the European Diabetes Forum (EUDF) here and connect with Bart Torbeyns on LinkedIn here.

Janne Sørensen: Being aware of one’s own biases is part of a patient-centered approach

The diversity of JACARDI’s experts is a tremendous asset to the project, as it brings many different perspectives to the table, according to Janne Sørensen, diversity expert at the University of Copenhagen in the Department of Public Health. As a member of JACARDI’s Scientific Advisory Board, she shines a light on how vulnerable groups are impacted by diabetes and cardiovascular disease, and how healthcare professionals can better answer their needs. Her message to people working in healthcare is to see the whole person in front of them and to consider implementing equity as a lifelong learning process.

What significance does JACARDI hold for you and your organisation in terms of its mission and values?

As a public health expert, one of the core elements of my work is addressing health inequalities and striving for greater health equity for all. JACARDI’s focus on combating these inequalities, particularly in the context of cardiovascular diseases and diabetes, resonates deeply with both my personal mission and the goals of my organization.

How do you see JACARDI’s role in tackling the increasing prevalence of cardiovascular diseases and diabetes in Europe?

Well, this is a big question and a significant challenge, as diabetes is on the rise. We need to stop its progression and bring the situation under control. JACARDI is a large initiative and, I believe, a serious attempt to address this challenge. You are confronting the problem head-on with innovative approaches. JACARDI positions itself at the heart of the EU’s efforts to tackle this issue. It is an impressive project, and I am very happy to be part of it.

How do you see our role in promoting equity in healthcare?

JACARDI plays a significant role here because it aims to address inequalities. In other words, we see disparities affecting many vulnerable groups who are significantly impacted by these health issues. For example, people with lower socio-economic status, migrants, ethnic minorities, and LGBT groups all have a higher prevalence of diabetes and cardiovascular diseases.

I must say this is an ambitious objective for such a large project, and it might be quite challenging to mainstream diversity, reach everyone, and ensure that everyone adopts principles of equity and diversity.

How do you see the significance of cultural diversity in the development of diabetes and CVD treatment? And what is the most important or critical aspect of this?

This is significant because you are addressing these particularly vulnerable groups. It is therefore crucial to ensure that you consider meeting people with their diverse identities, vulnerabilities, and characteristics in order to effectively tackle the issues of diabetes and cardiovascular disease.

Implementing diversity can be challenging, but you’ve brought it to the forefront. Ideally, the insights gained from this project will inspire experts to incorporate them into their own work and organizations long after it concludes. JACARDI brings together a diverse group of experts, representing a wide range of educational backgrounds, nationalities, ethnicities, and experiences. This diversity is a tremendous asset to the project, as it brings many different perspectives to the table.

You are providing training for healthcare professionals on cultural diversity. Are there questions that professionals often ask?

Some people ask why it is necessary to discuss diversity, especially if they are already working with a patient-centered approach. My answer is always that while you might have a patient-centered approach, it doesn’t necessarily require that you, as a health professional, reflect on your own background, biases, and stereotypes. Understanding these is crucial when interacting with patients.

Additionally, we discuss health inequalities: that many people are worse off in terms of health because they have fewer opportunities from the beginning of their lives, simply because they belong to specific groups and face discrimination within the healthcare system. These differences also exist among various groups, such as people with disabilities or those from the LGBT community, and so on.

What is your message to healthcare professionals then?

My message is that you need to see the whole person in front of you, in addition to knowing the prevalence of diseases and risk factors and being able to diagnose. This is not easy, because as a healthcare professional, you have to consider many things during a short appointment.

I believe we are trying to improve communication and interaction between healthcare professionals and patients by raising awareness of the disadvantages the patient may face, as well as the risk factors. At the same time, it’s important to recognize what professionals bring into the meetings.

This is a lifelong learning process, not something that can be mastered through a short course. Applying these lessons in practice after completing a course is an entirely different challenge.

Janne Sørensen is a specialist in diversity and diversity competence, based at the Department of Public Health at the University of Copenhagen. Her work focuses on integrating diversity competence into medical education through training programs for students and healthcare professionals. Alongside her teaching, Janne conducts research on various aspects of diversity and addresses issues of discrimination within medical student communities.

Learn more about Janne Sørensen and her work and connect on LinkedIn.

Birgit Beger: An EU Cardiovascular Health Plan is the best way forward

Birgit Beger, CEO of the European Heart Network (EHN) and member of JACARDI’s Stakeholder Advisory Board, strongly believes that investment in health is a win-win for society overall. With the EU stepping up with the European Commission’s recent announcement of an EU Cardiovascular Health Plan, Birgit Beger shares her hope for an ambitious proposal by the European Commission in line with the work undertaken for the European Beating Cancer Plan. She sees JACARDI’s importance in leveraging knowledge and best practices across Europe and underscores the need to involve stakeholders early on, because they can help bridge the gap between policy and practice.

What significance does JACARDI hold for you and your organization in terms of its mission and values?

In line with EHN Strategy, JACARDI, with its joint action of European pilot projects to reduce the burden of cardiovascular diseases and diabetes, mirrors one of EHN’s core pillars: prevention. Furthermore, EHN supports JACARDI’s overarching goal of improving CVDs and diabetes in terms of disease management.

In your experience, what are the most pressing challenges in implementing effective healthcare policy at both the EU and national levels in the area of cardiovascular disease prevention?

There is a disconnect between the political and healthcare practice levels. For example, the pressing societal burden of cardiovascular diseases has only recently come to the attention of policy makers at national and European levels. The recognition of the urgency for action is growing and yet, given that we are speaking these days about a permacrisis, many politicians are dealing with a myriad of urgent priorities simultaneously. However, as has always been argued, investment in health is a win-win for society overall, financially, for social inclusion and cohesion. This is particularly relevant for cardiovascular disease (CVD), which is the number one cause of mortality and morbidity in Europe and globally.

EHN’s vision is that “every person in Europe should grow up and live in a sustainable environment which promotes cardiovascular health. Premature and preventable deaths due to cardiovascular diseases should be reduced by 30% in 2030. State of the art, personalised care and quality of life should be accessible and attainable for those born or living with CVD”. In this context, taking legislative action to reduce the impact of major risk factors for CVD (unhealthy nutrition, smoking, physical inactivity, air pollution and climate change, but also hypertension, obesity and high cholesterol levels) are of the utmost importance in reducing the burden of CVD.

This being said, not all CVDs are preventable. Therefore, it is equally important to invest in early detection and management of cardiovascular diseases, thereby enabling people who are at high risk of developing CVD, or who have already contracted a CVD, to actively manage their condition, so that they can live to a mature age, with a good quality of life.

What do you see as the key success factors for achieving long-term impact in reducing the prevalence and burden of CVD? How is the EU CVH plan coming along?

Indeed, EHN believes that an EU Cardiovascular Health Plan is the best way forward since it represents a structured and financed approach to combat the cardiovascular burden on society and the increasing CVD numbers, which are already emerging for 2023 and 2024 following the Covid-19 pandemic. We see that many Member States are taking action for national CVH plans, that the European Parliament is supporting a European CVH plan and we are pleased to hear that the European Commission President Ursula von der Leyen identified CVD as a new health priority for her renewed mandate. It is important that the European Commission comes forward with an ambitious proposal in line with the work undertaken for the European Beating Cancer Plan.

Therefore, we applaud wholeheartedly the recent adoption of Council Conclusions on the Improvement of Cardiovascular Health in the EU on 3 December 2024, as well as the commitment from the new Health Commissioner, Olivér Várhelyi, to develop a European Cardiovascular Health Plan. EHN particularly welcomes references made to prevention, women’s health and research. A strong focus on the patients’ voice will be a decisive quality element of such a future European plan. It will hopefully trigger efforts at national level to improve or develop national cardiovascular health plans.

How important are EU-funded projects like JACARDI in addressing NCDs, and what role do they play in complementing the work of other organizations like EHN?

JACARDI has a real potential to implement policy at national level and to make tangible inroads at the European level. It is very promising that so many health institutions are involved in leveraging knowledge and best practices across Europe. EHN is there to support and advise on the work, but also help to disseminate results across its membership.

As CEO of the European Heart Network, you have a unique perspective on the dynamics of cardiovascular health advocacy across Europe. What lessons from your experience there could be applied to projects like JACARDI to maximize their effectiveness?

It is most important to involve stakeholders early on because they can help bridge the gap between policy and practice. As EHN, we can bring expertise to the table from our members at national level, namely, the patient experience, but we also speak to national and European policy makers. In this way, projects such as JACARDI can be fast-tracked further to develop results, through our consolidated support, which will work in practice through the informed connections these layers will bring.

About Birgit Beger

With 22 years of EU public policy experience focusing on leading European Associations like Medical Doctors, Lawyers, Health NGOs, Birgit Beger is a well-respected senior executive. Birgit is a qualified lawyer and skilled communicator with senior management experience and diplomatic outreach to all political levels, both at the national and European level. She has brought considerable added value to the leadership roles she has held during her tenures as CEO of the European Cancer Organisation (ECCO), and as Secretary General of the Standing Committee of European Doctors (CPME). She is a member of WHO-Europe Regional Director’s Advisory Council on Innovation for Noncommunicable Diseases (the NCD Advisory Council) and is the CEO of the European Heart Network, a leading advocate and key partner in shaping and advancing the European Cardiovascular Health Plan.

Learn more about the European Heart Network here & connect on LinkedIn here.